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Abstract A cDNA encoding a short polypeptide blocker of K+ 
channels, kaliotoxin 2 (KTX2), from the venom of the North 
African scorpion Androctonus australis was expressed in the 
periplasmic space of Escherichia coli. KTX2 was produced as a 
fusion protein with the maltose binding protein followed by the 
recognition site for factor Xa or enterokinase preceding the first 
amino acid residue of the toxin. The fully refolded recombinant 
KTX2 (rKTX2) was obtained (0.15-0.30 mg/1 of culture) and was 
indistinguishable from the native toxin according to chemical and 
biological criteria. An N-extended analogue of KTX2 exhibiting 
three additional residues was also expressed. This analogue had 
1000-fold less affinity for the 125I-kaliotoxin binding site on rat 
brain synaptosomes than KTX2. Conformational models of 
KTX2 and its mutant were designed by amino acid replacement 
using the structure of agitoxin 2 from Leiurus quinquestriatus as 
template, to try to understand the decrease in affinity for the 
receptor. 
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1. Introduction 
Efforts to characterise minor components in scorpion ven-
oms have led to the discovery of short toxins (31-40 amino 
acids residues, three disulphide bridges) able to act on differ-
ent types of K+ channels [1,2]. The diversity of K+ channels is 
large [3,4] and there has been a profusion of research for new 
selective ligands in order to elucidate their mechanisms of 
action and pharmacological significance. A K+ channel block-
er, kaliotoxin (KTX), has been characterised from the venom 
of the Moroccan scorpion Androctonus mauretanicus; KTX is 
a single 4-kDa polypeptide chain (38 amino acid residues, 
three disulphide bridges) which acts on the intermediate con-
ductance Ca2+-activated K+ channel in invertebrate neurons 
(IKCa) and on voltage-dependent K+ channels (Kv) of the 
mammalian nervous system [5,6]. A new KTX-like peptide, 
KTX2, was isolated from the venom of the North African 
scorpion Androctonus australis [7]. It is a 37-amino acid resi-
due peptide, with a non-amidated COOH-terminus, which dis-
plays 76% sequence identity with KTX. KTX and KTX2 dif-
fer by their N-terminal portion and also by the replacement of 
His34 and Arg31 in KTX by Asp and Gly in KTX2. These two 
residues are located in the COOH-terminal region which is 
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highly conserved among 'short toxins' active on K+ channels 
and which has been assumed to be involved in the interaction 
with the pore of the channel [8-11]. Most of the conserved 
amino acid residues are located in an antiparallel ß-sheet 
made of two short strands connected by a turn [12,13]. To 
obtain enough material for structural and additional biolog-
ical studies of KTX2, it was necessary to produce the toxin by 
chemical synthesis or in heterologous expression systems. The 
cDNA of KTX2 has already been obtained from a cDNA 
library of A. australis venom glands [7,14], by polymerase 
chain reaction (PCR), using degenerate primers targeted 
against the highly conserved amino acid cluster. It is a 370-
bp cDNA, encoding the KTX2 precursor which is constituted 
of a signal peptide (22 amino acid residues) followed by the 
mature KTX2. We used this cDNA to produce a recombinant 
KTX2 (rKTX2), directly addressed as fusion protein to the 
periplasmic space of Escherichia coli, as well as an NH2-ex-
tended mutant exhibiting 1000-fold less affinity for its receptor 
site on rat brain synaptosomes. 
2. Materials and methods 
2.1. Materials 
Synthetic KTX (sKTX) was synthesised by. Dr Romi in the labo-
ratory according to [6]. Specific antibodies against sKTX were ob-
tained in rabbit [7]. Restriction and DNA modifying enzymes were 
purchased from Boehringer Mannheim. [oe-35S]dATP used for nucleo-
tide sequencing and 125I-K for radiolabelling of KTX were from 
Amersham. pMAL-p, 6220 bp, was from Biolab. UV-grade acetoni-
trile was from Fisons Scientific, trifluoroacetic acid was from Baker. 
Other solvents and reagents were analytical grade commercial prod-
ucts from Sigma and Merck. The water used to prepare solvents and 
buffers was obtained with the Milli/Ro/Milli Q system from Millipore. 
2.2. Construction of the recombinant KTX2 gene 
The template used for PCR was the double strand cDNA of KTX2 
[7] inserted into pBluescript SK+ (Stratagene). Oligonucleotide pri-
mers were synthesised on an Applied Biosystems 381A DNA synthes-
iser. They were as follows: constructions 1 and 2:5 ' AAA ATC CAC 
GTG AGA ATT CCA GTG TCA TGT 3' as forward primer con-
taining a PmH restriction enzyme site (underlined) and corresponding 
to positions 77-99 of the KTX2 cDNA, i.e. NH2-terminal residues 1-
7 of KTX2; construction 3: 5' GAA AGG CCT GAT GAC GAT 
GAC AAG GTG AGA ATT CCA GTG TCA TGT 3' as forward 
primer carrying a StuI restriction enzyme site (underlined) and corre-
sponding to five codons encoding an enterokinase cleavage site and 
positions 77-99 of the KTX2 cDNA, i.e. NH2-terminal residues 1-7 
of KTX2. For the three different constructions, the reverse primer 5' 
AAA CTG CAG TCA CTT TGG TGT AC A ATC GCA 3' was used 
carrying a PstI restriction enzyme site (underlined) and corresponding 
to positions 192-171 of KTX2 cDNA, i.e. the stop codon and COOH-
terminal residues 37-32 of KTX2. 
2.3. PCR 
PCR was performed and the PCR products were visualised as de-
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scribed [7]. The band with the appropriate size was recovered, purified 
using the Wizard PCR Prep DNA Purification System (Promega) 
according to the manufacturer's instructions and reamplified by a 
second PCR reaction in the same conditions. 
2.4. Sequence analysis of the constructions 
The purified PCR products were filled in with dNTPs using the 
Klenow fragment according to standard methods [15], digested with 
restriction enzymes corresponding to the restriction sites at the 5'-ends 
of both primers and ligated into the vector pMAL-p. E. coli DH5a 
was used for plasmid propagation. Transformants containing the cor-
rectly constructed DNA fragments were analysed by restriction digest 
with EcoRV and Nsft using standard techniques [15] and sequenced 
with Sequenase (Amersham) using the Sanger dideoxynucleotide chain 
termination method [16] according to the supplier's instructions. 
2.5. Production of fusion proteins and purification by affinity 
chromatography 
E. coli strain DH5a (BRL) carrying the gene fusions was grown at 
37°C in Circle Grow medium (Bio-101) containing 50 ug/ml ampicil-
lin. When the cell density had reached <460o=0.5, induction was ini-
tiated by the addition of 0.2 mM isopropyl ß-D-thiogalactoside 
(IPTG). Cells were harvested 3 h after addition of IPTG and peri-
plasmic extracts prepared by osmotic shock [17]. The periplasmic ex-
tracts (400 ml) were applied to an amylose affinity resin (2.5X7 cm 
column) in 20 mM Tris-HCl, 0.2 mM NaCl, 1 mM EDTA buffer, pH 
7.4. After elution of the unbound proteins (the optical density of the 
eluant being around 0.02), the bound maltose binding protein (MBP)-
KTX2 fusion protein was eluted from the amylose resin in the same 
buffer containing 10 mM maltose. Then, the MBP-KTX2 was desalted 
using Microsep microconcentrators (Filtron Technology Corporation) 
with a 10 K cutoff. 
2.6. Polyacrylamide gel electrophoresis 
SDS-PAGE of proteins was performed on 12% Phast-Gel (Phast-
System, Pharmacia) and gels were stained with silver according to the 
manufacturer's instructions. 
2.7. Slot blots 
Nitrocellulose membrane (Bio-Rad Laboratories) were used for slot 
blots according to the protocol supplied with the Bio-Rad Immuno-
Blot assay kit anti-rabbit IgG alkaline phosphatase conjugate. The 
anti-KTX serum was used at a 104-fold dilution. 
2.8. Cleavage of MBP-KTX2 fusion protein 
Various conditions for cleavage of the MBP-KTX2 (obtained with 
construction 1) and MBP-KIH-KTX2 (obtained with construction 2) 
by factor Xa (three different sources: Boehringer, Sigma, Bachern) 
were tried: fusion proteins (concentration of 1 mg/ml, 35 ug/assay) 
were incubated in 20 mM Tris-HCl, 100 mM NaCl and 2 mM CaCl2 
buffer, pH 8, at different ratios of factor Xa to the fusion proteins (3-
15% mass/mass), for different times and at various temperatures (24 h 
or 48 h at 4°C, 26°C or 37°C). To increase the cleavage yield, guani-
dine chlorohydrate (0.1-1 M), urea (0.1-1 M), SDS (0.1-1%), aceto-
nitrile (10% v/v) or guanidine chlorohydrate+acetonitrile, urea+aceto-
nitrile, SDS+acetonitrile (amounts as above) were added. To cleave 
the MBP-KTX2 (obtained with construction 1), factor Xa was also 
replaced by trypsin or arginine C-protease (Sigma) in the same con-
ditions. To cleave MBP-KTX2 (obtained with construction 3) bovine 
enterokinase (two different sources: Sigma, Biozyme; 3-15% mass/ 
mass) was used in 50 mM Tris-HCl, 5 mM CaCl2, pH 8 or pH 5.2 
with acetonitrile (10% v/v) at 26°C for 24 h. Guanidine chlorohydrate, 
urea, SDS (amounts as described above) were also added to the sam-
ples to increase the cleavage yield. 
2.9. High performance liquid chromatography (HPLC) 
The recombinant toxins were purified by reverse-phase HPLC at 
25°C on a Merck (4 X 250 mm) analytical column prepacked with 5 (xm 
of Lichrospher 100 RP-18 on a Waters Associates system as previ-
ously described [5]. HPLC on an anionic exchanger (DEAE-3SW 
Spherogel TSK column from Beckman, 7.5X7.5 mm) was also per-
formed (solvent A, water, solvent B, 1 M ammonium acetate, pH 7.6). 
Detailed descriptions of all the Chromatographie steps are given in the 
text and figure legends. Samples for biological assays were lyophilised 
in the presence of 0.1% BSA. 
2.10. Protein chemistry 
2.10.1. Amino acid sequence. An Applied Biosystems 476A se-
quencer and the recommended program cycles were used for auto-
mated Edman degradation. Phenylthiohydantoin derivatives were 
characterised by HPLC as described [7], 
B 
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Fig. 1. Schematic diagram of plasmid pMAL-p constructions used 
for the production of MBP-KTX2 and MBP-KIH-KTX2. A: 
pMAL-p-(fac.Xa)-KTX2. B: pMAL-p-(fac.Xa)-KIH-KTX2. C: 
pMAL-p-(fac.Xa-EnK)-KTX2. Three ligations were performed using 
the 6.2-kbp Stul-Pstl fragment of pMAL-p (downstream of the 
malE gene) and (A) the 124-bp Pmä-Pstl PCR fragment containing 
the region encoding mature KTX2; (B) the 133-bp Pmä-Pstl PCR 
product encoding the KIH-KTX2 peptide; (C) the 139-bp Stul-Pstl 
PCR fragment encoding KTX2 downstream of the enterokinase 
cleavage site. 
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2.10.2. Mass spectrometry. Electrospray mass spectrometry of the 
recombinant KTX2 was performed by Neosystem as already de-
scribed [7]. 
2.11. Radioiodination of sKTX 
His34 in synthetic KTX was radiolabelled using Iodogen as already 
described [7]. Specific radioactivities of 2000 Ci/nmol were routinely 
obtained. The radioactivity was counted using a Packard Crystal II 
multidetector system spectrometer. 
2.12. Competition binding assay on rat brain synaptosomes 
Assays were performed on the synaptosomal fraction P2 from rat 
brain as previously described [6]. See also figure legends for experi-
mental detail. 
2.13. Modelling 
Homology modelling was performed on a Silicon Graphics R3000 
Indigo workstation using MODELLER [18]. Target (KTX2 or KIH-
KTX2) and template (agitoxin 2, AgTX2) [19] sequences were auto-
matically aligned by MODELLER, which subsequently generated the 
coordinates of both models. Successive energy minimisations and sim-
ulated annealing cycles were run, taking into account a set of con-
straints including probability density functions compiled from the 
template structures and from a set of reference protein structures 
[18]. Hydrogen atoms were generated on the final models which 
were briefly energy-minimised, with all backbone atoms constrained. 
Models were checked with PROCHECK [20] for geometry compli-
ance. 
3. Results 
Our first aim was to obtain a fully active recombinant 
KTX2. Due to the existence of several potential tryptic cleav-
age sites in the KTX2 molecule (R2, R23, K26, K31), it was 
necessary to use highly selective enzymatic conditions. BrCN 
cleavage from a fusion protein including MBP and KTX2 was 
also impossible because of the presence of M22 and M28- The 
factor Xa cleavage site and also an enterokinase site were 
therefore used. 
3.1. Construction of the expression vectors and expression of 
the fusion proteins 
The cDNA encoding KTX2 was amplified by PCR with 
non-degenerate forward and reverse primers. The non-coding 
regions and the signal peptide of the toxin were removed from 
the cDNA and specific restriction enzymes sites were added to 
facilitate insertion into the pMAL-p expression vector, such 
that a gene fusion could be constructed. There is a Sacl, Kpnl, 
Eagl, BamHl polylinker between the malE gene and the oli-
gonucleotides encoding the factor Xa cleavage site, 5' to a 
Stul site. Three different constructions were made (Fig. 1). 
In the first construction, the KTX2 sequence was inserted 
between the Stul and the PstI sites, downstream of the se-
quence encoding the factor Xa cleavage site located at the 3' 
end of the malE gene (Fig. 1A). Due to a failure of PmK to 
cleave all the amplified PCR product before its insertion into 
pMAL-p, an additional construction was found by sequence 
analysis of the different products. This fortuitous construct 
contained three codons encoding the amino acid sequence 
Fig. 2. Characterization of MBP-KTX2. A : SDS-PAGE of periplasmic extracts from non-induced and IPTG-induced E. coli cells carrying the 
MBP-KTX2 gene fusion. Lanes 1 and 2, induced and non-induced cells harbouring construction 1 (data not shown for constructions 2 and 3, 
but similar results were obtained); lanes 3 and 4, induced and non-induced cells harbouring pMAL-p as control; lane 5, molecular weight 
markers; arrows indicate: a, MBP-KTX2; b, MBP. B: Purification of MBP-KTX2 using maltose and an amylose affinity column. Amylose col-
umn (2.5X7 cm) in 20 mM Tris-HCl, 0.2 mM NaCl, 1 mM EDTA buffer, pH 7.4; flow rate 20 ml/h; 400 ml of periplasmic extract each time; 
when the flow-through reached OD 0.02 at 280 nm, elution buffer containing maltose was added; fractions of 2 ml were collected. C: Slot blots 
of the affinity-purified proteins and controls. Lane A, 1, 2, 3, sKTX as positive control (respectively 1 |i.g, 0.1 ug, 10 ng); 5, synthetic peptide 
(10 |ig) as negative control; Lane B, 1, 2, a-scorpion toxin as negative control (respectively 1 |xg, 0.1 |xg); 4, 5, MBP-KTX2 (respectively 4 |ig, 
0.4 |xg); the anti-sKTX serum was used at a 104-fold dilution and revealed using an anti-rabbit IgG-alkaline phosphatase conjugate. D: Analy-
sis on SDS-PAGE of the affinity-purified proteins after silver staining. Lane 1, molecular weight markers; lanes 2, 3, 4 and 5, respectively frac-
tions 6 (baseline), 7, 8, 9 (top) purified in B. Arrows indicate: a, monomeric form of MBP-KTX2; b, MBP; c, dimeric form of MBP-KTX2. 
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Fig. 3. Purification of rKTX2. RP-C18 column; solvent A, 0.1% 
TFA; solvent B, acetonitrile+0.1% TFA; linear gradient from 5% 
to 80% of B in A during 25 min, followed by an isocratic step at 
80% of B in A; flow rate 1 ml/min; absorbance was monitored at 
230 nm with a 1 Optical Density Unit Full Scale. Chromatogram 
A: digest of construction 1 with factor Xa (40 ug of MBP-KTX2); 
chromatogram B : digest of construction 2 with enterokinase (40 ug 
of MBP-KTX2); rKTX2 eluted at 20 min and MBP-KTX2 at 26 
min. 
KIH in frame between the factor Xa and KTX2 sequences 
and thus encoded a KTX2 mutant with three additional res-
idues at its NH2-terminus (Fig. IB). In the third construction, 
five codons encoding an enterokinase cleavage site (DDDDK) 
were added at the blunt-end Stu\ restriction site 5' to the 
factor Xa sequence such that the linker between MBP and 
KTX2 in the fusion was IEGRPDDDDK (Fig. 1C). These 
various constructs were used to transform E. coli and were 
expressed upon IPTG induction. Periplasmic extracts (before 
and after induction) of the transformants and of cells contain-
ing pMAL-p as controls were subjected to SDS-PAGE (Fig. 
2A). Intense bands corresponding to the molecular weights of 
the expected proteins were obtained : 40 kDa for MBP and 44 
kDa for MBP-KTX2. Large-scale cultures (1 1) of the trans-
formants were grown, induced with IPTG and the periplasmic 
extracts prepared 3 h later. MBP derivatives were then puri-
fied from these extracts on an amylose affinity column as 
explained in Section 2 (Fig. 2B). The yields of affinity-purified 
proteins were 15-20 mg/1 of culture, estimated by absorbance 
at 280 nm. The purified material was desalted and concen-
trated, then analysed by dot blots (Fig. 2C). No specific anti-
bodies against natural KTX2 were available. Thus, specific 
antibodies against sKTX were used for blotting experiments. 
These antibodies were previously unable to recognise native 
KTX2 in liquid RIA [7], in spite of high sequence similarities 
between the two toxins (76%). This suggested that conforma-
tional epitopes were preferentially recognised in solution as 
already demonstrated with long cc-scorpion toxins [21]. Anal-
yses with synthetic peptides derived from KTX indicated that, 
in liquid RIA, the 12 NH2-terminal residues, which differed 
from those of KTX2, are important for antibody recognition 
[7]. Immunoblot experiments were performed with sKTX as 
positive control, MBP-KTX2, and a long a-scorpion toxin 
and a synthetic peptide as negative controls. This synthetic 
peptide (12 amino acids residues) was designed according to 
the N-terminal sequence of a novel toxin acting on K+ chan-
nels (unpublished) and was not expected to react with the 
anti-sKTX antibodies. As expected, the a-scorpion toxin 
and the synthetic peptide were not recognised by the anti-
sKTX antibodies. However, MBP-KTX2 bound these anti-
bodies, indicating that the fusion contained sKTX epitopes. 
Analysis of the affinity-purified proteins by SDS-PAGE 
showed three major bands (Fig. 2D): one at 40 kDa corre-
sponding to MBP (probably due to deletion of the insert 
during the culture), one at 44 kDa corresponding to MBP-
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Fig. 4. Competition experiments for binding to rat brain synaptoso-
mal fraction. Membranes (30 ug/assay) in 25 mM Tris-HCl, pH 7.4, 
50 mM NaCl, 0.1% BSA were incubated for 1 h at 26°C with 125I-
sKTX (40 pM final concentration) and each of a series of concen-
trations of protein to test. The experiment was stopped by centrifu-
gation at 11 000 X g for 5 min. The membrane pellets were washed 
twice with 1 ml of cold washing buffer (20 mM Tris-HCl, 150 mM 
NaCl, 0.1% BSA, pH 7.4) and the radioactivity bound to the mem-
brane was counted. B0 is the binding of 125l-sKTX in the absence 
of competitor and B is the binding in the presence of the indicated 
concentrations of sKTX (•), rKTX2 (o), rK!H-KTX2 (■), 
rGSIEGRKIH-KTX2 (o) or MBP-KTX2 ( A ) . Non-specific binding 
determined in the presence of O.f uM sKTX was about 25%. Data 
points correspond to duplicates from which non-specific binding has 
been subtracted. The standard error of the mean of the data was 
around 5%. 
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Fig. 5. Comparison between the structures of AgTX2, KTX2, and KIH-KTX2. A: Ribbon models of AgTX2, KTX2, and KIH-KTX2, ob-
tained by homology modelling with MODELLER. Some residues are displayed as space-filling atoms: residues AgTX2 1-2, KTX2 1, and KIH 
1-4 (with the additional residue 1 of AgTX2 and the three additional residues of KIH in magenta) and also residues AgTX2 27-31, KTX2 26-
30, and KIH-KTX2 29-33, believed to be important for toxin binding. B: Amino acid sequences of AgTX2, KTX2, KIH-KTX2. Additional 
residues (in comparison with the N-terminal of KTX2) are in magenta; the residues displayed as space-filling atoms in A are in bold. 
KTX2 and one at 88 kDa corresponding to dimers due to 
disulphide pairing between two MBP-KTX2 (this was demon-
strated by SDS-PAGE and blot of the proteins after reduction 
by dithioerythritol, not shown). As MBP-KTX2 contained six 
more positive charges than MBP, the three different proteins 
could be easily purified by HPLC on an anion exchange 
DEAE-TSK column (data not shown). The MBP-KTX2 con-
stituted 35% of the total affinity-purified proteins, thus about 
5-7 mg of fusion protein. 
3.2. Enzymatic cleavage of MBP-KTX2 and characterisation 
of the recombinant toxin 
The effects of buffer composition (with various amounts of 
or without different ratios of SDS, urea, guanidine chlorohy-
drate and/or acetonitrile), pH, enzyme/substrate ratio, en-
zymes from different sources, digestion time and temperature 
on cleavage were investigated. 
3.2.1. Cleavage of constructions 1 and 2 with factor Xa. 
Factor Xa was totally unable to cleave MBP-KTX2 under any 
conditions (Fig. 3A). MBP-KIH-KTX2 was treated with fac-
tor Xa and the products purified by HPLC (not shown). Two 
protein fractions were obtained and their sequences deter-
mined. The cleavage (50-70% according to the experimental 
conditions) was after a GR encoded by the oligonucleotide in 
the BamHl site of the polylinker (at a sequence ...SSSVPGR/ 
GSIEGRKIH-KTX2), thus giving a KTX2 with nine addi-
tional residues at the N-terminus (rGSIEGRKIH-KTX2). 
Some cleavage (10%) occurred at the factor Xa site. A frac-
tion corresponding to a recombinant KIH-KTX2 (KTX2 with 
three additional residues at the NH2-terminal end, thus called 
rKIH-KTX2) eluted within a retention time of 21 min. 
3.2.2. Cleavage of construction 3 with enterokinase. 25-
30% of the fusion protein was cleaved. The best recovery yield 
was obtained with the enterokinase from Biozyme, at pH 8.1 
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and at 26°C for 24 h, with an enzyme/substrate ratio of 15%. 
In all cases, cleavage was totally inhibited by SDS, urea and 
guanidine chlorohydrate, but increased by addition of aceto-
nitrile (10% v/v). So, 0.15-0.30 mg/1 of culture is expected. 
rKTX2 was purified by HPLC at a retention time of 20 
min, corresponding to that of the natural KTX2 (Fig. 3B). 
Its N-terminal sequence (position 1-10) was determined three 
times after three different cleavages and was as expected. A 
molecular mass of 4022.8 Da was obtained by electrospray 
mass spectrometry, in accordance with the molecular mass 
of 4021.6 Da previously found for native KTX2 and with 
the expected theoretical mass of 4021.7 Da calculated from 
amino acid composition and sequence data. Purified rKTX2, 
rKIH-KTX2, rGSIEGRKIH-KTX2 and MBP-KTX2 were 
tested in competition experiments with 125I-sKTX for binding 
to rat brain synaptosomes (Fig. 4). They all inhibited the 
binding of 125I-sKTX to its receptor site: rKIH-KTX2 with 
an IC50 of 30 nM, rGSIEGRKIH-KTX2 and MBP-KTX2 
with an IC50 of 0.1 uM and rKTX2 with an IC50 of 30 pM. 
By intracerebroventricular injection into mice, rKTX2 was 
found to be fully active (lethal dose=35 ng), but rKIH-
KTX2, rGSIEGRKIH-KTX2 and MBP-KTX2 were inactive 
up to 3.5 p,g. 
3.3. Modelling of KTX2 and KIH-KTX2 
Conformational models of KTX2 and KIH-KTX2 were 
designed by sequence alignment with AgTX2, as sequence 
identity between KTX2 and AgTX2 is higher than that be-
tween KTX2 and KTX. The positions of the six half-cystines 
were used as topological references. Models of KTX2 and of 
its mutant KIH-KTX2 were obtained within less than 2 h of 
Central Processing Unit (CPU) time. They were highly rated 
in Ramachandran plot and overall PROCHECK tests. Fig. 5 
shows the two models and that of AgTX2 for comparison 
[19]. 
4. Discussion 
To investigate the molecular basis of receptor recognition 
by the related toxins active on K+ channels, our laboratory 
has previously studied structure-activity relationships using 
chemically synthesised analogues [6,22,23]. The three-dimen-
sional structures of some of these analogues, including 
KTX(l-37) [13] and P05-NH2, a peptide active on the apa-
min-sensitive Ca2+-activated K+ channel [24], have been 
solved using 2D 'H-NMR spectroscopy. The truncated 
KTX(l-37) analogue shows some structural differences with 
other related K+ channel blockers. To perform additional 
structural studies by two-, three- and four-dimensional 
NMR of 13C-, 15N-labelled toxin, it is necessary to develop 
a bacterial expression system. 
We successfully produced KTX2 as a fusion protein in the 
periplasm of E. coli, using the plasmid pMAL-p. The yield of 
the desired fusion product isolated from the periplasmic space 
was 5-7 mg/1 of culture, giving 300 |xg rKTX2 after cleavage 
from the fusion protein by enterokinase and purification by 
HPLC. We were unable to recover rKTX2 from a fusion 
protein containing a factor Xa cleavage site. Attempts at 
cleavage with Arg C-protease and trypsin were unsuccessful. 
We suspect a strong interaction between the acidic MBP 
(Pi=5) and KTX2 (Pi> 10), and this may occlude the recog-
nition site. However, factor Xa cleaved MBP-KIH-KTX2, 
poorly yielding rKIH-KTX2. Most cleavage events were six 
amino acid residues upstream of the expected site, but the 
three additional residues in the N-terminal position of 
KTX2 seem to improve recognition by the protease. 
Heterologous expression of synthetic genes for other small 
scorpion toxins, like charybdotoxin (ChTX) from Leiurus 
quinquestriatus [25] or margatoxin (MgTX) from Centruroides 
margaritatus [26], has been described in E. coli. The fusion 
proteins produced in the cytoplasm were cleaved by factor 
Xa after purification and the resulting toxins refolded 'in vi-
tro'. The expression yield of toxin was in some cases 3-4 mg/1. 
So, the yield of rKTX2 produced in the periplasm is low 
compared to the amounts of the other toxins active on the 
K+ channel obtained by heterologous gene expression in the 
cytoplasm of E. coli. Also, dendrotoxin K ( D T X K ) from black 
mamba, a potent inhibitor of a voltage-dependent K+ current, 
and able to compete with 125I-sKTX for its receptor site on 
rat brain synaptosomes, has been produced as a MBP fusion 
protein in both the cytoplasm and the periplasm of E. coli. 
The best yield of active toxin (1.5-2 mg/1) was obtained after 
cleavage by factor Xa of the M B P - D T X K produced in the 
periplasm [27]. 
For the first time, the influence of an additional N-terminal 
length on the biological activity of a small scorpion toxin 
active on the K+ channel was investigated. The ability of 
ChTX to block IKCa at motor nerve terminals or BKCa 
(big conductance calcium-activated K+ channel) of smooth 
muscles falls dramatically when the N-terminal region is trun-
cated [28,29]. Acetylation or biotinylation of the amino group 
reduced binding (10-fold) of MgTX to Kvl.3, suggesting the 
involvement of the N-terminal amino group in the toxin ac-
tivity [30]. KTX2, like MgTX, exhibits a very high affinity (25 
pM) for Kvl.3 channels (Crest, unpublished data). Our results 
are consistent with those in the literature, since addition of 
three amino acid residues (KIH) to the N-terminus of KTX2 
reduces the activity by a factor of 1000. It is clearly visible (in 
magenta in Fig. 5) that residues 1-3 of KIH-KTX2 are bulky 
enough to hinder the Lys26 (Lys27 in AgTX2) binding to the 
channel site, or other residues of the ß-sheet area involved in 
the receptor recognition [6,8]. The replacement of Arg31 and 
His34 (in AgTX2) by Gly30 and Asp33 (in KTX2) may account 
for the lower affinity of KTX2 for Kvl.3 channels: 4 pM for 
AgTX2 [31] and 25 pM for KTX2 (Crest, personal commu-
nication). It has been demonstrated, using analogues of ChTX 
[8,32,33], KTX [10] and AgTX2 [34], that Lys27 can interact 
with negatively charged residues of the pore and is essential to 
the activity of the toxins. In KTX, it would interact directly 
with Asp402 (or with the cluster of four Asp402s) of the Kvl.3 
channel [10]. Also, the binding affinity of AgTX2 to the Shak-
er K+ channel may depends on Arg24 and Arg31 and the 
mobility of their side chains may facilitate the formation of 
the toxin-receptor complex [34,19]. All published toxin-recep-
tor interactions support the existence of a shallow vestibule at 
the external entrance to the pore: the width of the Kvl.3 
vestibule is estimated to be 28-34 A [10] and that of the 
Shaker vestibule 22-30 A [34]. Additional N-terminal residues 
of rKIH-KTX2 may also increase the contiguous surface area 
thought to be projected into the mouth of the channel, pre-
cluding multiple contacts between the vestibule and the toxin. 
However, the addition of a longer fragment to the N-terminus 
of KTX2, as is the case for rGSIEGRKIH-KTX2, did not 
greatly decrease the activity. The competition between 125I-
C. Legros et al.lFEBS Letters 417 (1997) 123-129 129 
sKTX and MBP-KTX2 for the K T X binding site on rat brain 
synaptosomes indicates that the residues involved in the inter-
action between K T X 2 and its receptor are still accessible. 
Acknowledgements: We gratefully thank Dr Andrej Sali who kindly 
provided MODELLER. 
References 
[1] Strong, P.N. (1990) Pharmacol. Ther. 46, 137-142. 
[2] Miller, C. (1995) Neuron 15, 5-10. 
[3] Pongs, O. (1993) Trends Pharmacol. Sei. 14, 435. 
[4] Chandy, K.G. and Gutman, G.A. (1993) Trends Pharmacol. Sei. 
14, 434. 
[5] Crest, M., Jacquet, G., Gola, M., Zerrouk, H., Benslimane, A., 
Rochat, H., Mansuelle, P. and Martin-Eauclaire, M.-F. (1992) J. 
Biol. Chem. 267, 1640-1647. 
[6] Romi, R., Crest, M., Gola, M., Sampieri, F., Jacquet, G., Zer-
rouk, H., Mansuelle, P., Sorokine, O., Van Dorsselaer, A., Ro-
chat, H., Martin-Eauclaire, M.-F. and Van Rietschoten, J. (1993) 
J. Biol. Chem. 268, 26302-26309. 
[7] Laraba-Djebari, F., Legros, C , Crest, M., Céard, B., Romi, R., 
Mansuelle, P., Jacquet, G., Van Rietschoten, J., Gola, M., Ro-
chat, H., Bougis, P.E. and Martin-Eauclaire, M.-F. (1994) J. Biol. 
Chem 269, 32835-32843. 
[8] Park, C.-S. and Miller, C. (1992) Biochemistry 31, 7749-7755. 
[9] Goldstein, S.A.N., Pheasant, D J . and Miller, C. (1994) Neuron 
12, 1377-1388. 
[10] Aiyar, J., Withka, J.M., Rizzi, J.P., Singleton, D.H., Andrews, 
G.C., Simon, M., Dethlefs, B., Lee, C.-L., Hall, J.E., Gutman, 
G.A. and Chandy, K.G. (1995) Neuron 15, 1169-1181. 
[11] Gross, A. and McKinnon, R. (1996) Neuron 16, 399^106. 
[12] Bontems, F., Roumestand, C , Gilquin, B., Menez, A. and Toma, 
F. (1991) Science 254, 1521-1523. 
[13] Fernandez, I., Romi, R., Szendeffy, S., Martin-Eauclaire, M.-F., 
Rochat, H., Van Rietschoten, J., Pons, M. and Giralt, E. (1994) 
Biochemistry 33, 14256-14263. 
[14] Bougis, P.E., Rochat, H. and Smith, L.A. (1989) J. Biol. Chem. 
264, 19259-19265. 
[15] Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) Molecular 
Cloning: A Laboratory Manual, Cold Spring Harbor Labora-
tory, Cold Spring Harbor, NY. 
[16: 
[IT 
[is: 
[i9: 
[2o: 
[21 
[22 
[23: 
[24] 
[25: 
[26 
[27 
[28: 
[29: 
[3o: 
[31 
[32 
[33: 
[34] 
Sanger, F., Nicklen, S. and Coulson, A.R. (1977) Proc. Nati. 
Acad. Sei. USA 74, 5463-5467. 
Riggs, P. (1990) in: Current Protocols in Molecular Biology (Au-
subel, F.M. et al., Eds.), Greene Associates/Wiley Interscience, 
New York. 
Sali, A. and Blundell, T.L. (1990) J. Mol. Biol. 234, 779-815. 
Krezel, A.M., Kasibhatla, C , Hidalgo, P., McKinnon, R. and 
Wagner, G. (1995) Protein Sei. 4, 1478-1489. 
Laskowski, R.A., MacArthur, M.W., Moss, D.S. and Thornton, 
J.M. (1993) J. Appl. Crystallogr. 26, 283-291. 
Granier, C , Novotny, J., Fontecilla-Camps, J.-C, Fourquet, P., 
El Ayeb, M. and Bahraoui, E. (1989) Mol. Immunol. 26, 503-
513. 
Sabatier, J.M., Zerrouk, H., Darbon, H., Mabrouk, K , Bensli-
mane, A., Rochat, H., Martin-Eauclaire, M.-F. and Van 
Rietschoten, J. (1993) Biochemistry 32, 2763-2770. 
Sabatier, J.M., Fremont, V., Mabrouk, K , Crest, M., Darbon, 
H., Rochat, H., Van Rietschoten, J. and Martin-Eauclaire, M.-F. 
(1994) Int. J. Peptide Protein Res. 43, 486^195. 
Meunier, S., Bernassau, J.M., Sabatier, J.M., Martin-Eauclaire, 
M.F., Van Rietschoten, J., Cambillau, C. and Darbon, H. (1993) 
Biochemistry 32, 11969-11976. 
Park, C.-S., Hausdorff, S.F. and Miller, C. (1991) Proc. Nati. 
Acad. Sei. USA 88, 2046-2050. 
Garcia-Calvo, M., Leonard, R.J., Novick, J., Stevens, S.P., 
Schmalhofer, W., Kaczorowski, G.J. and Garcia, M.L. (1993) 
J. Biol. Chem. 268, 18866-18874. 
Smith, A.L., Lafaye, P.J., La Penotiere, H.F., Spain, T. and 
Dolly, O. (1993) Biochemistry 32, 5692-5697. 
Harvey, A.L., Vantapour, H., Rowan, E.G., Pinkasfeld, S., Vita, 
C , Menez, A. and Martin-Eauclaire, M.-F. (1993) Toxicon 33, 
425^136. 
Giangiacomo, K.M., Sugg, E.E., Garcia-Galvo, M., Leonard, 
R.J., McManus, O.B., Kaczorowski, G.J. and Garcia, M.L. 
(1993) Biochemistry 32, 2363-2370. 
Bednareck, M.A., Bugianesi, R.M., Leonard, R.J. and Felix, J.P. 
(1994) Biochem. Biophys. Res. Commun. 198, 619-625. 
Garcia, M.L., Garcia-Calvo, M., Hidalgo, P., Lee, A. and Mac 
Kinnon, R. (1994) Biochemistry 33, 6834-6839. 
Goldstein, S.A.N. and Miller, C. (1993) Biophys. J. 65, 1613-
1619. 
Stampe, P., Kolmakova-Partensky, L. and Miller, C. (1994) Bio-
chemistry 33, 443^150. 
Hidalgo, P. and McKinnon, R. (1995) Science 268, 307-310. 
